When I was diagnosed with Stage III Triple Positive IDC in December 2013, I went through the standard treatments - neoadjuvant AC+TH with six rounds of Perjeta. I was told by my oncologist that a pathologic complete response carried the best prognosis but that I wasn't likely to have one because I was highly hormone positive and started out with a large tumor burden. When I pushed him about doing more chemo after surgery if I had residual cancer, he told me that extra chemo was not standard for hormone positive, but I was welcome to join a clinical trial.
Wanting to be as aggressive as possible, I had already decided even before my post-surgery pathology came back that I would do a trial if I had residual disease. When I learned that I had a small tumor and two lymph nodes still positive, I immediately looked into trials I qualified for. I came up with two for patients with residual cancer after neoadjuvant chemo. One was a Halaven trial at my local cancer center, and one was a Kadcyla (TDM-1) trial at Moffitt, a three-hour drive away from me.
While the logistics of the Kadcyla trial (known as the KATHERINE trial) were more complicated than those of the Halaven trial, I didn't care about that. I wanted the best treatment possible and a trial targeting HER2 seemed like the best bet. But the problem was that with the KATHERINE trial, I would have a 50% chance of being randomized to Herceptin only and with the Halaven trial, I was guaranteed to get the treatment drug. It was a very difficult decision, but in the end I decided to roll the dice on the KATHERINE trial. And for once things went my way. I was randomized to the Kadcyla arm.
Currently, I receive 14 cycles of Kadcyla every three weeks. I had my first treatment on September 22, 2014 and I [had] my last treatment June 24th. It is more tiring being part of a trial than it is getting standard treatment. Every treatment involves labwork, a doctor's visit and observation periods. I also can only get certain testing, like my routine ECHO at the trial facility. So with frequent, long, exhausting visits to Tampa, I have found it hard to hold a job and get back to normal life.
But I am so glad that I decided to participate in a trial. For one, I hope getting treatment beyond the standard of care will improve my prognosis. But even if it doesn't, I am happy that my contributions will help science and the many women who will come after me.
-- Bad_At_Usernames, KATHERINE trial
The opinions expressed in this article are the author's own and do not necessarily represent those of Breastcancer.org nor are they intended as a substitute for the medical advice of physicians.
Can we help guide you?
Create a profile for better recommendations
Breast self-exam, or regularly examining your breasts on your own, can be an important way to...
Eating When You Have Nausea and Vomiting
Almost all breast cancer treatments have varying degrees of risk for nausea and vomiting. Some...
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....